Tvardi Therapeutics (TVRD) shares sank nearly 84% amid heavy trading after the company said Monday its phase 2 clinical trial of TTI-101 as a potential treatment for idiopathic pulmonary fibrosis failed to meet its goals.

Intraday trading volume jumped to over 5.55 million from a daily average of about 42,000.

Beyond Meat (BYND) said Monday its offer to exchange existing zero-interest convertible notes due in 2027 for new 7% secured notes due in 2030 and shares of common stock was subscribed with 96.92% of the holders tendering in for the exchange.

Shares slumped roughly 46% as intraday trading volume soared to nearly 117.5 million from a daily average of about 4.9 million.

Fastenal's (FAST) Q3 earnings came in below market estimates amid sluggish industrial production, while the company's sales rose in line with expectations.

Shares dropped 5.9% as intraday trading volume climbed to about 10.8 million from a daily average of roughly 6.3 million.

Price: 6.68, Change: -34.92, Percent Change: -83.94